European Journal of Medicinal Chemistry p. 516 - 530 (2018)
Update date:2022-09-26
Topics:
Shahin, Mai I.
Roy, Joyeeta
Hanafi, Maha
Wang, Dongyao
Luesakul, Urarika
Chai, Yifeng
Muangsin, Nongnuj
Lasheen, Deena S.
Abou El Ella, Dalal A.
Abouzid, Khaled A.
Neamati, Nouri
No new and effective treatments have been approved for the treatment of esophageal squamous cell carcinoma (ESCC) in the past decade. Cisplatin and 5-fluoruracil are the most commonly used drugs for this disease. In order to develop a new class of drugs effective in our ESCC phenotypic screens, we began a systematic approach to generate novel compounds based on the 2-oxo-1,2-dihydroquinoline-4-carboxamide fragment. Herein, we report on the synthesis and initial assessment of 55 new analogues in two ESCC cell lines. Some of the active analogues with IC50 values around 10 μM were tested in three additional cell lines. Our structure-activity relationships revealed remarkable alterations in the anti proliferative activities upon modest chemical modifications and autophagy modulation is a suggested mechanism of action.
View MoreSuzhou Health Chemicals Co., Ltd.
website:http://www.healthchems.com
Contact:13776257979
Address:No. 338, Jingang Avenue,
Changzhou Welton Chemical Co., Ltd,
Contact:0086-519-85910828,85920537,85912897
Address:No.8 Jinlong Road, Binjiang Park, Changzhou, Jiangsu, China.
Shanghai PuYi Chem-Tech Co.,Ltd.
Contact:+86-21-57687505-227
Address:3 Floor, Building 11, No 201 MinYi Road, Songjiang District, Shanghai 201612, China
Contact:+86-577-65618087-605
Address:Room 402, Unit 4 Xinhu Bldg. Waitan Ruian City, Zhejiang China.
Contact:(1) 206-3550089
Address:5115 NE 8TH PL, Renton, WA 98059 USA
Doi:10.1021/ol1011295
(2010)Doi:10.1021/acs.jnatprod.0c00344
(2020)Doi:10.1021/ja510475n
(2014)Doi:10.1021/jo00288a033
(1990)Doi:10.1007/s12039-020-01874-2
(2021)Doi:10.1002/anie.201000590
(2010)